Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Sexton

Showing results (81-90 of 137) with videos related to

Pageof 14
Sort By:
Annals of the Rheumatic Diseases|August 14, 2021
Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatmentKaren Holten, Nina Paulshus Sundlisater, Siri Lillegraven, et al.
Infection Control and Hospital Epidemiology|December 13, 2023
Persistent colonization of <i>Candida auris</i> among inpatients rescreened as part of a weekly surveillance programSebastian P Arenas, Patrice J Persad, Samira Patel, et al.
Therapeutic Drug Monitoring|February 2, 2026
The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III TrialJohanna E Gehin, Rolf A Klaasen, Eirik K Kristianslund, et al.
Frontiers in Medicine|February 27, 2025
Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC studyGaoyang Li, Shrikant S Kolan, Franco Grimolizzi, et al.
RMD Open|November 13, 2024
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trialJohanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, et al.
Rheumatology (Oxford, England)|September 29, 2023
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseasesIngrid Jyssum, Johanna E Gehin, Joseph Sexton, et al.
RMD Open|December 20, 2018
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trialLena Bugge Nordberg, Siri Lillegraven, Anna-Birgitte Aga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2025
Improved consistency of Candida auris colonization screening with an anterior nares and hands composite sampleLuisa F López, Sebastian Arenas, Adriana Jimenez, et al.
RMD Open|November 30, 2018
Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD studyVibeke Norvang, Joseph Sexton, Eirik K Kristianslund, et al.
Arthritis Research & Therapy|July 14, 2018
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapyMaria Karolina Jonsson, Aase Haj Hensvold, Monika Hansson, et al.
Pageof 14

Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Annals of the Rheumatic Diseases|August 14, 2021
Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatmentKaren Holten, Nina Paulshus Sundlisater, Siri Lillegraven, et al.
Infection Control and Hospital Epidemiology|December 13, 2023
Persistent colonization of <i>Candida auris</i> among inpatients rescreened as part of a weekly surveillance programSebastian P Arenas, Patrice J Persad, Samira Patel, et al.
Therapeutic Drug Monitoring|February 2, 2026
The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III TrialJohanna E Gehin, Rolf A Klaasen, Eirik K Kristianslund, et al.
Frontiers in Medicine|February 27, 2025
Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC studyGaoyang Li, Shrikant S Kolan, Franco Grimolizzi, et al.
RMD Open|November 13, 2024
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trialJohanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, et al.
Rheumatology (Oxford, England)|September 29, 2023
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseasesIngrid Jyssum, Johanna E Gehin, Joseph Sexton, et al.
RMD Open|December 20, 2018
Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trialLena Bugge Nordberg, Siri Lillegraven, Anna-Birgitte Aga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2025
Improved consistency of Candida auris colonization screening with an anterior nares and hands composite sampleLuisa F López, Sebastian Arenas, Adriana Jimenez, et al.
RMD Open|November 30, 2018
Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD studyVibeke Norvang, Joseph Sexton, Eirik K Kristianslund, et al.
Arthritis Research & Therapy|July 14, 2018
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapyMaria Karolina Jonsson, Aase Haj Hensvold, Monika Hansson, et al.
Pageof 14